X‐ray structure and kinetic properties of ornithine transcarbamoylase from the human parasite <i>Giardia lamblia</i> (2009)

Ornithine transcarbamoylase (OTC; EC 2.1.3.3, also known as ornithine carbamoyltransferase) catalyzes the reversible conversion of citrulline to carbamoyl phosphate (CP) and L-ornithine in the arginine dihydrolase pathway. This pathway is used by a number of microorganisms, including Giardia lamblia to generate ATP fermentatively from arginine.1, 2G. lamblia OCT (glOTC) was shown to be one of the 16 immunodominant proteins, underscoring the importance of the arginine catabolism pathway in the characterization of the parasite.3 Moreover, recently glOTC was identified as one of the major proteins released into the medium after brief interaction of Giardia with human intestinal epithelial cells. Therefore, it was suggested that targeting glOTC for immunoneutralization may represent a useful therapeutic strategy for treating giardiasis.4 Multiple crystal structures of OTCs were determined from prokaryotic and eukaryotic organisms. Currently, 26 structures of OTCs from 10 organisms have been deposited in the PDB5 under the OTC or ornithine carbamoyltransferase names. In this work, we have undertaken glOTC purification and crystal structure determination to assist with the characterization of this attractive therapeutic drug target for the potential treatment of the parasitic infection. We have compared the active sites of glOTC and human OTC (hOTC)6 to identify potential structural features, which may be exploited to develop selective inhibitors of the parasitic enzyme. The trophozoites of G. lamblia isolate WB were grown as described previously.7 The genomic DNA was isolated by using the DNA STAT kit (Stratagene). The gene encoding glOTC was amplified using PfuTurbo DNA polymerase (Stratagene), genomic DNA, and 5′- and 3′-end primers. The PCR product was inserted into the pDEST-HisMBP expression vector as described by Waugh and coworkers.8 For protein production, the glOTC was expressed in E. coli strain BL21(DE3)Star as a maltose binding protein (MBP) fusion product. Cells were grown in Overnight Express Instant TB autoinduction medium (Novagen) for 20 h at 30°C. The cells were broken by sonication, and the soluble fraction was applied on a Ni-NTA affinity column. After elution and concentration, the glOTC MBP-fusion protein was applied onto a preparative size exclusion column, Sephacryl 100. MBP was removed by treatment of the fusion protein with tobacco etch virus (TEV) protease,9 at a molar ratio of 60:1, followed by chromatography on a Ni-NTA affinity column. The protein was further purified by ion-exchange chromatography on a SOURCE 15 Q column (Amersham Biosciences). Fractions containing protein were collected, dialyzed against 50 mM Tris-HCl (pH 7.5) and 50 mM NaCl, and concentrated up to 35 mg/mL. Protein integrity and purity was assessed by polyacrylamide gel electrophoresis in the presence of SDS. The native mass was measured by size exclusion chromatography using a Superdex-200 HR 10/30 column (Amersham Bioscience) in conjunction with an ÄKTA purifier 10. Reaction solutions (1 mL) initially contained L-citrulline at varied concentration (0.5–5 fold Km) and 20 mM sodium phosphate (or sodium phosphate at varied concentration (0.5–5 fold Km) and 60 mM L-citrulline), glOTC, 2 mM glucose, 0.9 mM ADP, 30 mM MgCl2, 0.2 mM NADP, 0.03 μMG. lamblia carbamate kinase, 10 U hexokinase, 5 U glucose 6-phosphate dehydrogenase in 50 mM Tris-HCl (pH 8.0, 37°C). The reaction progress was monitored at 340 nm (Δϵ = 6.2 mM−1 cm−1). The initial velocities (Vo) measured as a function of the concentration of the varied substrate, [S], were fitted with KinetAsyst to the equation Vo = Vmax[S]/(Km + [S]) to obtain the maximum velocity (Vmax) and the Michaelis constant (Km). The kcat was calculated from the ratio of the Vmax and the enzyme concentration. Reaction solutions (1 mL) initially contained L-ornithine at varied concentration (0.5–5 fold Km), 10 mM carbamoyl phosphate (or carbamoyl phosphate at varied concentration (0.5–5 fold Km), and 10 mM L-ornithine) and glOTC in 50 mM Tris-HCl (pH 8.0) at 37°C. The reaction progress was determined using a fixed-time colorimetric assay for L-citrulline.10 The kcat and Km values were calculated from the initial velocity data as described earlier. PALO was synthesized as described previously by Morizono et al.11 The competitive inhibition constant for PALO was determined by fitting the initial velocities measured for reactions initially containing (0.0, 0.05, 0.09, or 0.13 μM PALO), L-citrulline (5–100 mM), 20 mM sodium phosphate, 2 mM glucose, 0.9 mM ADP, 30 mM MgCl2, 0.2 mM NADP, 0.03 μM carbamate kinase, 10 U hexokinase, 5 U glucose 6-phosphate dehydrogenase, and glOTC in 50 mM Tris-HCl (pH 8.0, 37°C) with KinetAsyst. The initial velocity data were analyzed using the equation Vo = Vmax[S]/(Km (1 + [I]/Ki) + [S]), where Ki is the inhibition constant and [I] is the PALO concentration. Crystals were obtained at 20°C by the vapor diffusion method in hanging drops. The protein solution was mixed with an equal volume of mother liquor containing 30% Polyethylene Glycol Monomethyl Ether 550, 0.1M NaCl, and 0.1M Bicine buffer (pH 9.0) and equilibrated against the mother liquor reservoir. The crystals diffracted X-rays to a resolution of 2.0 Å and required a period of 3–5 days to appear. Diffraction data were acquired using an RAXIS IV++ image plate detector mounted on a Rigaku rotating anode MicroMax 007 X-ray generator (Rigaku MSC). Data processing was carried out using the CrystalClear program, version 1.3.6 (Rigaku MSC). The statistics of data collection are provided in Table I. The structure was determined by the Molecular Replacement method using the computer program Phaser12 and the Pyrococcus furiosus OTC structure13 as the search model. The difference Fourier maps indicated that some glOTC segments had to be modified compared with the P. furiosus OTC (residues 3–4, 34–37, 149–156, 210–216, and 323–325). Structure refinement was carried out using the CNS program.14 The resulting models were inspected and modified on a graphics workstation using program “O”.15 Water molecules were added to the model based on the Fo − Fc Difference Fourier electron density map (where Fo and Fc are the observed and calculated structure factors, respectively), using peaks with density ≥3σ as the acceptance criteria. Refinement statistics are provided in Table I. The N-terminally His-tagged MBP fusion glOTC was expressed in soluble form in E. coli and remained soluble after digestion with TEV protease and removal of the MBP. The mass of the purified glOTC was determined to be ∼90 kDa (using the molecular marker from Amersham), which based on a theoretical subunit mass of 36494.2 Da defines the quaternary structure as homotrimeric. The steady-state catalytic rate constants measured at pH 8.0 and 37°C are reported in Table II. The bisubstrate analog PALO is a competitive inhibitor versus L-citrulline at saturating phosphate (10-fold Km). Because the phosphate is expected to compete with the PALO for binding to the free enzyme, the experimental Ki value of 0.025 ± 0.009 μM is expected to be somewhat larger than the actual Ki value. The kinetic and inhibition constants of glOTC are in the range observed for other OTCs and similar to that of the human11 and porcine16 enzymes. The glOTC crystal contains one protein molecule in the asymmetric unit and the crystallographic 3-fold symmetry generates a trimeric structure [Fig. 1(A)], consistent with the association state measured in solution (vide supra). Human OTC also associates into trimers. Crystal contacts are mediated by a Ni2+ ion that presumably originated from the Ni-NTA column. The Ni2+ occupies a special position on the 3-fold symmetry axis, and it coordinates three His71 residues and three water molecules. The model of the glOTC molecule includes 304 of the 326 amino acid residues. Missing from the model are residues that were not associated with interpretable electron density: one N-terminal residue remaining after TEV cleavage (Gly), three OTC N-terminal residues, and 17 residues of two flexible loops associated with the active site (loop1—residues 78–87, and loop2—residues 244–251). Both of these loops play an important role in sequestering the substrates from bulk solvent. Overall fold, active site architecture of glOTC, and sequence alignment of glOTC and hOTC. (A) Ribbon diagram representation of the protein trimer. The Ni2+ ion at the center of the trimer is shown as magenta sphere. (B) Stereoscopic view of the glOTC active site superposed with the hOTC/PALO active site. The carbon atoms are colored green (glOTC) and magenta (hOTC). Other atomic colors are as follows: oxygen, red; nitrogen, blue; phosphor, orange; and sulfur, yellow. Black residue labels correspond to glOTC, except that the two residues labeled in magenta color (His117 of a neighboring subunit and Met268) are hOTC residues that are disordered in the glOTC structure (Ser82 and Tyr245, respectively). (C) Sequence alignment of glOTC and hOTC. Identical residues are blocked in blue and residues surrounding the active site are indicated by red triangles. As with all OTCs, the molecule consists of N-terminal and C-terminal domains of similar size, known as the CP and aminoacid binding domains. A DALI17 search identified the Mycobacterium tuberculosis OTC as the glOTC closest structure (pdb code 2i6u, with Z-score of 42.8 and a root-mean-squares deviation (RMSD) of 1.2 Å for 289 aligned α-carbon atoms that share 37% sequence identity). Each domain exhibits an α/β topology with a central β-pleated sheet flanked by α-helices. The domains are connected by two interdomain helices (residues 133–149 and 301–332), and the cleft between two domains comprises the active site. The CP binding domains are located in the interior of the trimer, and the aminoacid binding domains are located further from the trimer center. By analogy to the many known OTC structures, residues from both domains are involved in catalysis. The glOTC is a potential anti giardiasis drug target, and therefore features that distinguish it from the human counterpart are of special interest for the development of selective inhibitors. The two enzymes share only 30% sequence identity, suggesting an opportunity to exploit their differences in drug development. In contrast to the catabolic glOTC, human OTC is a ureotelic enzyme that catalyzes the formation of citrulline from CP and L-ornithine in the urea cycle.18 Superposition of the glOTC and hOTC structures using the hOTC/PALO complex structure (pdb entry code 1oth)6 yielded a RMSD of 1.6 Å for 288 aligned α-carbon atoms. The superposition and the sequence alignment show that the active sites of both enzymes are very similar and most of the residues around the bound PALO are identical [Fig. 1(B,C)]. However, there are two notable exceptions related to residues located on the disordered loops of the glOTC structure. His117 in hOTC is located on a loop analogous to the disordered loop 1 of glOTC. The His117 from an adjacent hOTC subunit interacts with the phosphonate group of PALO [Fig. 1(B)]. The glOTC loop1 is one amino acid residue longer than that of hOTC and its sequence, GANSNVGGKE (rsidues 78–87) does not contain a His residue. Modeling indicates that the most probable equivalent glOTC residue to the hOTC His117 is Ser81. This is an important difference because all ureotelic OTCs have His at this position linking the phosphate oxygen of CP to Asn121 (hOTC numbering) in a potential pathway for transferring a proton between the solvent and CP.6 The second significant sequence difference between the hOTC and glOTC active sites occurs in the disordered loop2 (glOTC residues 244–251). In hOTC, Met286 is stationed close to the carboxyl end of the bound PALO [Fig. 1(B)]. In contrast to hOTC, the equivalent residue in glOTC sequence is Tyr245, which introduces different space and electrostatic constraints. Other residues of both loops may play an important role in defining the active site cleft, in affecting ligand interactions and in sequestering the catalytic site from solvent. Yet, these loops exhibit no sequence homology between hOTC and glOTC, thus providing opportunities for designing selective inhibitors. Structures of liganded glOTC will provide better insight into strategies of inhibitor design. The PDB entry code is 3grf.